EP3782987A4 - Benzopyrazole compound used as rho kinase inhibitor - Google Patents

Benzopyrazole compound used as rho kinase inhibitor Download PDF

Info

Publication number
EP3782987A4
EP3782987A4 EP19788388.7A EP19788388A EP3782987A4 EP 3782987 A4 EP3782987 A4 EP 3782987A4 EP 19788388 A EP19788388 A EP 19788388A EP 3782987 A4 EP3782987 A4 EP 3782987A4
Authority
EP
European Patent Office
Prior art keywords
compound used
kinase inhibitor
rho kinase
benzopyrazole
benzopyrazole compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19788388.7A
Other languages
German (de)
French (fr)
Other versions
EP3782987A1 (en
Inventor
Lingyun Wu
Jun Yin
Cailin WANG
Zheming XIAO
Jian Li
Shuhui Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of EP3782987A1 publication Critical patent/EP3782987A1/en
Publication of EP3782987A4 publication Critical patent/EP3782987A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP19788388.7A 2018-04-18 2019-04-18 Benzopyrazole compound used as rho kinase inhibitor Pending EP3782987A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810349362 2018-04-18
CN201811221303 2018-10-19
PCT/CN2019/083210 WO2019201297A1 (en) 2018-04-18 2019-04-18 Benzopyrazole compound used as rho kinase inhibitor

Publications (2)

Publication Number Publication Date
EP3782987A1 EP3782987A1 (en) 2021-02-24
EP3782987A4 true EP3782987A4 (en) 2021-05-19

Family

ID=68239949

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19788388.7A Pending EP3782987A4 (en) 2018-04-18 2019-04-18 Benzopyrazole compound used as rho kinase inhibitor

Country Status (5)

Country Link
US (1) US11345678B2 (en)
EP (1) EP3782987A4 (en)
JP (1) JP7187575B2 (en)
CN (1) CN112020496B (en)
WO (1) WO2019201297A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021038419A1 (en) * 2019-08-23 2021-03-04 Insilico Medicine Ip Limited Kinase inhibitors and methods of synthesis and treatment
US11702400B2 (en) * 2019-10-18 2023-07-18 Medshine Discovery Inc. Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors
CN116438175A (en) * 2020-11-11 2023-07-14 南京明德新药研发有限公司 Benzourea ring derivative and preparation method and application thereof
CN113214172A (en) * 2021-04-25 2021-08-06 西南大学 Preparation method of fluconazole intermediate reductive amination product
CN114181139B (en) * 2021-12-27 2023-12-08 四川仁安药业有限责任公司 Synthesis method of 5-halogenated nicotinic acid
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519754A (en) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション Compound
CR9465A (en) 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
CA2700988A1 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
CN101790526A (en) 2007-06-08 2010-07-28 雅培制药有限公司 5-heteroaryl substituted indazoles as kinase inhibitors
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
US20120202793A1 (en) 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
ES2556350T3 (en) * 2009-08-10 2016-01-15 Samumed, Llc Indazole inhibitors of the Wnt signaling pathway and its therapeutic uses
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2012135697A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
HRP20220913T1 (en) 2012-10-05 2022-10-28 Kadmon Corporation, Llc Rho kinase inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
AU2017351216C1 (en) 2016-10-24 2021-10-14 Translational Drug Development, Llc Amide compounds as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP3782987A1 (en) 2021-02-24
JP7187575B2 (en) 2022-12-12
US20210371393A1 (en) 2021-12-02
JP2021522201A (en) 2021-08-30
CN112020496B (en) 2023-04-28
WO2019201297A1 (en) 2019-10-24
US11345678B2 (en) 2022-05-31
CN112020496A (en) 2020-12-01

Similar Documents

Publication Publication Date Title
EP3656769A4 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
EP3752491A4 (en) Heterocyclic compounds as kinase inhibitors
EP3836923A4 (en) Pyrrolo - dipyridine compounds
EP3806858A4 (en) Kinase inhibitor salts and compositions thereof
EP3843714A4 (en) Cd73 inhibitors
EP3782987A4 (en) Benzopyrazole compound used as rho kinase inhibitor
EP3889150A4 (en) Compound serving as irak inhibitor
EP3733671A4 (en) Amino-fluoropiperidine derivative as kinase inhibitor
EP3804707A4 (en) Kinase inhibitor
EP3464275A4 (en) Egfr inhibitor compounds
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
EP3787635A4 (en) Cd73 inhibitors
EP3902805A4 (en) Cyclin-dependent kinase inhibitors
EP3733673A4 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
EP3817736A4 (en) Pikfyve inhibitors
EP4003993A4 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
EP3999072A4 (en) Boron-containing rho kinase inhibitors
EP4003986A4 (en) Inhibitor compounds
EP3927700A4 (en) Kinase inhibitors
GB201819126D0 (en) Inhibitor compounds
EP3532479A4 (en) Amide compounds as kinase inhibitors
EP3749646A4 (en) Heteroaryl compounds as kinase inhibitor
EP3819299A4 (en) Hypoxanthine compound
EP3638237A4 (en) Aminothiazole compounds as protein kinase inhibitors
GB201914860D0 (en) Inhibitor compounds

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20210420

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 231/56 20060101AFI20210414BHEP

Ipc: C07D 401/04 20060101ALI20210414BHEP

Ipc: C07D 403/04 20060101ALI20210414BHEP

Ipc: C07D 403/12 20060101ALI20210414BHEP

Ipc: A61K 31/416 20060101ALI20210414BHEP

Ipc: A61P 11/00 20060101ALI20210414BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230214